Figure 2.
PFS from start of lenalidomide for MDS/AML, NHM and non‐SPM groups. Two‐year progression‐free survival was 50% (95% CI, 11.10–80.37%) in the MDS/AML group, 60% (95% CI, 12.57–88.18%) in the NHM group and 22.28% (95% CI, 16.58–28.53%) in the Non‐SPM group, Log‐rank P = 0.077 Wilcoxon P = 0.016.